Pencil Beam Scanning Proton Beam Radiotherapy for the Management of Abdominal Neuroblastoma

Launched by THE CHRISTIE NHS FOUNDATION TRUST · Jan 27, 2025

Keywords

ClinConnect Summary

The clinical trial titled "SUPERMAN" is exploring the use of an advanced type of treatment called Pencil Beam Scanning Proton Beam Therapy (PBT) for children and young people with a type of cancer known as abdominal neuroblastoma. This trial is part of a larger program that aims to find out which patients will benefit most from proton therapy compared to the more commonly used photon radiotherapy. The main goal of the SUPERMAN study is to determine the best treatment methods for these patients and to improve how PBT is monitored and adjusted during treatment.

To be eligible for this trial, patients must have a confirmed diagnosis of abdominal neuroblastoma and be fit for radical radiotherapy. They need to give written consent, which means they or their guardians agree to participate and allow their data to be used for research. Additionally, female patients who could become pregnant must agree to use effective contraception during treatment. This trial is not yet recruiting participants, but it aims to help ensure that young patients receive the best possible care while minimizing side effects from radiation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient with histologically confirmed abdominal or abdominal-pelvic neuroblastoma who are eligible and fit for radical radiotherapy.
• • Written informed consent from patient, parent or guardian - this includes consent for the minimum baseline, treatment and follow up assessments; and for their data to be stored and used for research, within the appropriate Proton Clinical Outcomes Units and NHS Proton Registry.
• • Patients registered female at birth of childbearing potential agree to use effective contraception between the planning Computed Tomography (CT) scan and the end of treatment.
• Exclusion Criteria:
• • Pregnant patient